Com-COV 3 study focuses on assessing a third dose booster vaccination for young people aged 12 to 15

The Com-COV 3 study has been commissioned through the NIHR and backed by £2.8 million government funding, with support from both the Vaccine Taskforce and National Institute for Health and Care Research (NIHR).

Related Keywords

United Kingdom ,Jakob Cramer ,Stanleyc Erck ,Matthew Snape ,Andrew Ustianowski ,Emily Henderson ,University Of Oxford ,Committee On Vaccination ,Care Research Wales ,Regulatory Agency ,Coalition For Epidemic Preparedness Innovations ,Pfizer ,National Institute For Health ,National Infection Specialty ,National Immunisation Schedule Evaluation Consortium ,Vaccination Programme ,Care Research ,Clinical Development ,Vaccine Taskforce ,National Institute ,Epidemic Preparedness Innovations ,Chief Investigator ,Joint National Infection Specialty Lead ,Chief Executive Officer ,Joint Committee ,Research ,Vaccine ,Adolescents ,Bacteria ,Covid 19 ,Efficacy ,Healthcare ,Hospital ,Immune Response ,Meningitis ,Meningitis Vaccine ,Paediatrics ,Pandemic ,Protein ,Public Health ,Running ,Cars ,Social Care ,Virus ,